AACR Annual Meeting 2021 – Poster 1080
Understanding the clinical resistance to kinase inhibitors

Discovery of Precision Oncology Drugs

NTRC provides in vitro drug discovery services focused on Precision Medicine. We help you to find the informed route to the clinic. Information can be found at www.oncolines.com

Understanding the clinical resistance to kinase inhibitors

The work presented in this poster elucidates the resistance mechanisms that cancer cell lines develop in vitro to the FGFR kinase inhibitor erdafitinib. Furthermore, it provides insight into inhibitors that are of potential use for treatment of erdafitinib-resistant cancers.

Access Cancer Cell Lines, Proliferation Assays and Bioinformatics Analysis to Find Patient Stratification Markers


Apply Combination Studies
to Identify
Novel Synergies


Use Cell-Based Assays
to Determine
Mechanism of Action


Information Needed?

Please contact us for more information